ERBB2 and breast carcinoma: A comparison of HER2 and EGR4-S protein expression on biopsies taken from eight different breast cancer patients diagnosed with HER2+ tumours (Figure 6D) showed that no EGR4-S protein could be detected in patients that received pre-biopsy treatment with drugs to suppress the HER2 pathway.